Abstracts

Disproportionality Analysis of Antiretrovirals With Suicidality Using FDA AERS Data

Background: An analysis of 4 ACTG studies, including 5332 subjects, identified an increase in the hazard of suicidality in efavirenz containing regimens compared to regimens containing atazanavir, atazanavir/ritonavir, lopinavir/ritonavir and zidovudine/lamivudine/abacavir. Rare but serious psychiatric adverse events (AEs), including suicide, have been included in postmarketing reports with efavirenz. We conducted a Multi-Item Gamma Poisson Shrinker…

HIV-replication control rates needed to prevent Neurocognitive Performance (NP) decline

Background: There are controversies regarding the level of HIV-suppression needed to prevent neurocognitive performance (NP) decline and the capacity of different ART types to prevent NP decline in HIV-suppressed patients. Methodology: Prospective comparison of NP decline rates in non-HIV controls (HIV-) and HIV-infected volunteers (HIV+) with >2 years of follow up presenting 1 of these…

Improvement of Depression and Anxiety After Discontinuation of Long-term Efavirenz Treatment

Background: Efavirenz is part of first-line antiretroviral therapy guidelines of WHO since 2002. The side effects of efavirenz are mainly neuropsychiatric and generally considered to be mild and transient. Recent studies indicate however that discontinuation of chronic efavirenz treatment can be observed in up to 50% of cases, possibly related to long term neuropsychiatric side-effects.…

HIV-1 Replication in Central Nervous System Increases Over Time on Protease Inhibitor Only Therapy

Background: Class sparing antiretroviral therapy with only protease inhibitors (PI) had been associated with central nervous system (CNS)-replication of HIV-1, probably due to impaired CNS penetration-effectiveness, but clinical confirmation is scarce. Objective was to evaluate risk factors for CNS replication of HIV-1 in patients on only boosted PI, versus nucleoside reverse transcriptase inhibitor (NRTI)-containing triple…

HIV Reactivation by the Histone Deacetylase Inhibitor Panobinostat: Effects on CNS

Background: Histone deacetylase inhibitors (HDACi) are currently being evaluated in experimental clinical trials for their ability to reactivate HIV-1 expression in latently infected cells with the aim of eradicating the latent HIV-1 reservoir. Panobinostat has previously been shown to reactivate HIV-1 expression in latently infected cells in vitro. However, caution has been raised that reactivation…

Accuracy of NEU Screen Detecting Cognitive Impairment in Virologically Suppressed HIV Patients

Background: The NEU Screen is a method recently proposed to help in the diagnosis of HIV-associated neurocognitive disorders (HAND). We tested this tool in a sample of virologically suppressed HIV-infected patients to investigate both sensitivity and specificity in comparison with those found in the original study. Methodology: In a sample of 156 virologically suppressed HIV-infected…

New Advanced EEG Technique to Monitor Early Brain Damage in Naïve HIV and Its Recovery During ART

Background: HIV patients may show a wide spectrum of cognitive deficits from mild forms up to dementia demostrable with neuropsychological tests; however earlier deficits can be hidden for years by brain neuroplasticity and these result in an absence of symptoms. Cognitive impairment is typically accompanied by a pathological increase of EEG rhythms at frequencies